VivoSeq
Respiratory

Chronic Obstructive Pulmonary Disease (COPD)

5

Pipeline Programs↗

12

Active Trials↗

9

Companies Involved↗

Chronic Obstructive Pulmonary Disease (COPD) is an early-stage landscape with 5 programs across 9 companies. The most active players are Expedition Therapeutics, Inc, Nanjing RegeneCore Biotech Co., Ltd., Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

34/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Expedition Therapeutics, Inc

2 programs

Phase 2N

Nanjing RegeneCore Biotech Co., Ltd.

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 3K

Kither Biotech Srl

1 program

PreclinicalAstellas logo

Astellas

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 50% of 8 pipeline programs.

Analysis

Trial Status

18

clinical trials

Recruiting6 · 33%
Completed6 · 33%
Not yet recruiting3 · 17%
Active, not recruiting3 · 17%

Clinical Trials

Trial Activity

18 trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Recruiting·NNanjing RegeneCore Biotech Co., Ltd.·Phase 2·NCT07402551·180 enrolled
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD
Recruiting·EExpedition Therapeutics, Inc·Phase 2·NCT07684820·600 enrolled
A Comparative Study of Ultrasonic and Conventional Spirometers in Patients With Chronic Respiratory Diseases
Recruiting·Fu Jen Catholic University·Preclinical·NCT07447232·100 enrolled
Prospective, Uncontrolled, Single-arm, Interventional Study With Pre-post Intervention Assessment on the Effect of the Simeox® Electro-medical Device on Residual Volume in Patients With COPD and Pulmonary Hyperinflation
Recruiting·AAzienda Socio Sanitaria Territoriale di Lodi·Preclinical·NCT07665931·23 enrolled
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06878261·990 enrolled
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06883305·990 enrolled
Clinical and dEmographic chaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in RussiA
Active, not recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07221981·2,038 enrolled
Retrospective Evaluation of the Implementation of a Digital Solution Supporting the Delivery of Pulmonary Rehabilitation Programs in Private Physiotherapy Practice
Active, not recruiting·AADIR Association·N/A·NCT07687836·50 enrolled
Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke
Active, not recruiting·—·Preclinical·NCT07118189·20 enrolled
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Ranging, Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics and Early Efficacy of Inhaled KIT2014 Over 7 Days of Treatment in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting·KKither Biotech Srl·Preclinical·NCT07668518·36 enrolled
DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction
Not yet recruiting·—·Preclinical·NCT07682168·15 enrolled
A Multicenter, Prospective, Double-blind, Randomized Controlled Study on the Impact of Decolonization Treatment on the Frequency of Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease Colonized With Pneumocystis Jirovecii
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Preclinical·NCT07665359·630 enrolled
Knee Extensors Force Control in People With Chronic Obstructive Pulmonary Disease
Completed·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·N/A·NCT06871670·36 enrolled
Personalized Biomedical Risk Assessment for Smoking Cessation in Chronic Obstructive Pulmonary Disease
Completed·UUnity Health Toronto·N/A·NCT04119934·83 enrolled
Influence of Cognitive Load on Postural Control in People With Chronic Obstructive Pulmonary Disease
Completed·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·N/A·NCT06863246·36 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)